Plain-English translation of NCT04918186 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether new combinations of immunotherapy medications — including , , , ENB-003, and — can help treat ovarian cancer that has come back after standard chemotherapy. Immunotherapy works by helping your body's immune system recognize and fight cancer cells. Researchers want to know if these medication combinations work better than the treatments most doctors currently offer.
Ovarian cancer that stops responding to platinum chemotherapy is very difficult to treat, and patients need better options. This medication is being studied to see if it can help women in this challenging situation live longer and healthier lives.
You likely qualify if…
You likely don't qualify if…
You would receive one of the new medication combinations through the study. You would need to have tumor biopsies (small samples of cancer tissue) taken before treatment starts and during treatment so doctors can see how the medication is affecting your cancer. You would have regular visits to check how you're responding and to monitor for side effects. The study is actively recruiting participants, so if you qualify and are interested, you can reach out to a participating cancer center.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States
Canada